Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine

Cellular and Molecular Immunology

Volumn 12, Issue 6, 2015, Pages 719-728

  He, Li Zhen ^a   Weidlick, Jeffrey ^a   Sisson, Crystal ^a   Marsh, Henry C ^a   Keler, Tibor ^a  

^a Celldex Therapeutics Inc   (United Kingdom)

Author keywords

GM CSF; hCG ; mannose receptor; Toll like receptor agonists

Indexed keywords

CANCER VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CD103 ANTIGEN; CD45 ANTIGEN; CDX 1307; CHORIONIC GONADOTROPIN BETA SUBUNIT; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B11; ONCOFETAL ANTIGEN; RESIQUIMOD; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; CARBOXYMETHYLCELLULOSE; CELL SURFACE RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; LECTIN; MANNOSE BINDING LECTIN; OLIGODEOXYRIBONUCLEOTIDE; POLYINOSINIC POLYCYTIDYLIC ACID; POLYLYSINE; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MIGRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; TISSUE DISTRIBUTION; UPREGULATION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPH NODE; LYMPHOCYTE COUNT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CARBOXYMETHYLCELLULOSE SODIUM; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; LECTINS, C-TYPE; LYMPH NODES; LYMPHOCYTE COUNT; MANNOSE-BINDING LECTINS; MICE; MICE, TRANSGENIC; OLIGODEOXYRIBONUCLEOTIDES; POLY I-C; POLYLYSINE; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TH1 CELLS; TOLL-LIKE RECEPTORS;

EID: 84946052759     PISSN: 16727681     EISSN: 20420226     Source Type: Journal    
DOI: 10.1038/cmi.2014.100     Document Type: Article

References (37)

1. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995; 375: 151-155.
2. Bozzacco L, Trumpfheller C, Siegal FP, Mehandru S, Markowitz M, Carrington M, et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD81 T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci USA 2007; 104: 1289-1294.
3. Cheong C, Choi JH, Vitale L, He LZ, Trumpfheller C, Bozzacco L, et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 2010; 116: 3828-3838.
4. Tsuji T, Matsuzaki J, Kelly MP, Ramakrishna V, Vitale L, He LZ, et al. Antibody-Targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD81 and CD41 T cell responses with broad antigen specificity. J Immunol 2011; 186: 1218-1227.
5. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD81 T cell tolerance. J Exp Med 2002; 196: 1627-1638.
6. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199: 815-824.
7. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769-779.
8. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7: 790-802.
9. Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 2005; 65: 7007-7012.
10. Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, Huang Y, et al. The microbial mimic poly IC induces durable and protective CD41 T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 2008; 105: 2574-2579.
11. Ramakrishna V, Treml JF, Vitale L, Connolly JE, ONeill T, Smith PA, et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol 2004; 172: 2845-2852.
12. Villadangos JA, Schnorrer P. Intrinsic and cooperative antigenpresenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 2007; 7: 543-555.
13. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315: 107-111.
14. Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials 2012; 33: 4229-4239.
15. Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005; 106: 1278-1285.
16. Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, et al. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 2011; 118: 4111-4119.
17. Idoyaga J, Cheong C, Suda K, Suda N, Kim JY, Lee H, et al. Cutting edge: langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. J Immunol 2008; 180: 3647-3650.
18. Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, et al. The C-Type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA31 myeloid dendritic cells. Blood 2012; 119: 2284-2292.
19. He LZ, Crocker A, Lee J, Mendoza-Ramirez J, Wang XT, Vitale LA, et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol 2007; 178: 6259-6267.
20. Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, Huang Y, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci USA 2011; 108: 2384-2389.
21. Chatterjee B, Smed-Sorensen A, Cohn L, Chalouni C, Vandlen R, Lee BC, et al. Internalization and endosomal degradation of receptorbound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood 2012; 120: 2011-2020.
22. Morse MA, Chapman R, Powderly J, Blackwell K, Keler T, Green J, et al. Phase I study utilizing a novel antigen-presenting cell-Targeted vaccine with Toll-like receptor stimulation to induce immunity to selfantigens in cancer patients. Clin Cancer Res 2011; 17: 4844-4853.
23. He LZ, Ramakrishna V, Connolly JE, Wang XT, Smith PA, Jones CL, et al. A novel human cancer vaccine elicits cellular responses to the tumor-Associated antigen, human chorionic gonadotropin beta. Clin Cancer Res 2004; 10: 1920-1927.
24. Taylor PR, Gordon S, Martinez-Pomares L. The mannose receptor: linking homeostasis and immunity through sugar recognition. Trends Immunol 2005; 26: 104-110.
25. Linehan SA, Martinez-Pomares L, Stahl PD, Gordon S. Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs: in situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia, and mesangial cells, but not dendritic cells. J Exp Med 1999; 189: 1961-1972.
26. McKenzie EJ, Taylor PR, Stillion RJ, Lucas AD, Harris J, Gordon S, et al. Mannose receptor expression and function define a new population of murine dendritic cells. J Immunol 2007; 178: 4975-4983.
27. McKenzie EJ, Su YP, Martinez-Pomares L. The mannose receptor, a bi-functional lectin with roles in homeostasis and immunity. Trends Glycosci Glycotechnol 2002; 14: 273-283.
28. Nigou J, Zelle-Rieser C, Gilleron M, Thurnher M, Puzo G. Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor. J Immunol 2001; 166: 7477-7485.
29. Burgdorf S, Lukacs-Kornek V, Kurts C. The mannose receptor mediates uptake of soluble but not of cell-Associated antigen for cross-presentation. J Immunol 2006; 176: 6770-6776.
30. Segura E, Albiston AL, Wicks IP, Chai SY, Villadangos JA. Different cross-presentation pathways in steady-state and inflammatory dendritic cells. Proc Natl Acad Sci USA 2009; 106: 20377-20381.
31. Chieppa M, Bianchi G, Doni A, del Prete A, Sironi M, Laskarin G, et al. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol 2003; 171: 4552-4560.
32. Kato M, Neil TK, Fearnley DB, McLellan AD, Vuckovic S, Hart DN. Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells. Int Immunol 2000; 12: 1511-1519.
33. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, et al. Dendritic cells require a systemic type I interferon response to mature and induceCD41Th1 immunity with poly IC as adjuvant. J Exp Med 2009; 206: 1589-1602.
34. Corbett AJ, Caminschi I, McKenzie BS, Brady JL, Wright MD, Mottram PL, et al. Antigen delivery via two molecules on the CD82 dendritic cell subset induces humoral immunity in the absence of conventional danger. Eur J Immunol 2005; 35: 2815-2825.
35. Zanoni I, Granucci F. Regulation of antigen uptake, migration, and lifespan of dendritic cell by Toll-like receptors. J Mol Med (Berl) 2010 88 873-880.
36. Cheong C, Matos I, Choi JH, Dandamudi DB, Shrestha E, Longhi MP, et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD2091 dendritic cells for immune T cell areas. Cell 2010; 143: 416-429.
37. Morse MA, Bradley DA, Keler T, Laliberte RJ, Green JA, Davis TA, et al. CDX-1307: a novel vaccine under study as treatment for muscleinvasive bladder cancer. Expert Rev Vaccines 2011; 10: 733-742.